

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. ABC-0001CIP	APPLICATION NO. 08-771,831
	APPLICANTS: Skurkovich <i>et al.</i>	
	FILED DATE: December 23, 1996	GROUP: 1876 1644

U.S. PTO
09/487979
01/26/00

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILED DATE
AS	A1	4,824,432	Apr. 25, 1989	Skurkovich <i>et al.</i>	604	+	Mar. 25, 1986
↓	B1	4,605,394	Aug. 12, 1986	Skurkovich <i>et al.</i>	604	4.5	Dec. 3, 1982
↓	C1	4,362,155	Dec. 7, 1982	Skurkovich <i>et al.</i>	128	214R	Mar. 24, 1981
	D1						
	E1						
	F1						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AS	R1	WO 92/16553	1 Oct. 1992	PCT	—	—	— Yes No
	S1						Yes No
	T1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)		
AS	AA	Aderka <i>et al.</i> , "Correlation between Serum Levels of Soluble Tumor Necrosis Factor Receptor and Disease Activity in Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 36(8):1111-1120 (1993).
AS	AB	Altomonte <i>et al.</i> , "Serum Levels of Interleukin-1b, Tumor Necrosis Factor-a and Interleukin-2 in Rheumatoid Arthritis, Correlation with Disease Activity," <i>Clin. Rheum.</i> 11(2):202-205 (1992)
AS	AC	Bevan <i>et al.</i> , "Interferon-Induced Parotitis and Epididymitis," <i>Lancet</i> 2:561 (1985).
AS	AD	Biglino <i>et al.</i> , "Spontaneous Release of Interferon as a Predictor of Clinical Evolution in HIV-Positive Subjects," <i>Infection</i> 19 (1):11/7-11/17 (1991).
AS	AE	Billard <i>et al.</i> , "IFN α in Vivo Enhances Tumor Necrosis Factor Receptor Levels on Hairy Cells," <i>J. Immunol.</i> 145:1713-1718 (Sept. 1990).
EXAMINER <i>Alm D. Elome</i>		DATE CONSIDERED 8-20-01 5-30-01
EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

FORM PTO-1449

ATTY. DOCKET NO.: ABC-0001CIP

APPLICATION NO.: 08 771,831

APPLICANTS: Skurkovich *et al.*

INFORMATION DISCLOSURE STATEMENT

FILING DATE: December 23, 1996

GROUP 1876 1644

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AS	AF	Braln <i>et al.</i> , "Effects of Tumor Necrosis Factor Alpha (TNF α) on Collagen Arthritis," <i>Lymphokine and Cytokine Res.</i> 11(5):253-256 (1992).
AD	AG	Brennan <i>et al.</i> , "TNF α - A Pivotal Role in Rheumatoid Arthritis," <i>Brit. J. Rheum.</i> 31(5):293-8 (1992).
AD	AH	Brod <i>et al.</i> , "Interferon- β , Treatment Decreases Tumor Necrosis Factor- α and Increases Interleukin-6 Production in Multiple Sclerosis," <i>Neurology</i> 46: 1633-1638 (June 1996).
AS	AI	Burton, "Human Monoclonal Antibodies, Achievement and Potential," <i>Hospital Practice</i> 667-74 (August 1992).
AS	AJ	Carpenter <i>et al.</i> , "The Pathogenesis of Autoimmunity in New Zealand Mice," <i>Lab Invest.</i> 23:628-634 (1970).
AS	AK	Chu <i>et al.</i> , "Detection of Cytokines at the Cartilage/Pannus Junction in Patients with Rheumatoid Arthritis: Implications for the Role of Cytokines in Cartilage Destruction and Repair," <i>Brit. J. Rheum.</i> 31(10):653-661 (1992).
AS	AL	Chazeraim <i>et al.</i> , "Rheumatoid Arthritis-like Disease after Alpha-Interferon Therapy," <i>Ann. Intern. Med.</i> 116:427 (Mar. 1992).
AS	AM	Conlon <i>et al.</i> , "Exacerbation of Symptoms of Autoimmune Disease in Patients Receiving Alpha-Interferon Therapy," <i>Cancer</i> 65:2237-2242 (1990).
AS	AN	Danis <i>et al.</i> , "Circulating Cytokine Levels in Patients with Rheumatoid Arthritis: Results of a Double Blind Trial with Sulphasalazine," <i>Ann. Rheum. Disease</i> 51(8):946-950 (1992).
AS	AO	Deleuran <i>et al.</i> , "Localization of Tumor Necrosis Factor Receptors in the Synovial Tissue and Cartilage-Pannus Junction in Patients with Rheumatoid Arthritis," <i>Arthritis Rheum.</i> 35(10):1170-78 (1992).
AS	AP	DeStefano <i>et al.</i> , "Acid-Labile Human Leukocyte Interferon in Homosexual Men with Kaposi's Sarcoma and Lymphadenopathy," <i>J. Infect. Disease</i> 146:451-455 (1982).
AS	AQ	Dorsett <i>et al.</i> , "Anti-Lymphocyte Antibodies in Patients with the Acquired Immune Deficiency Syndrome," <i>Am. J. Med.</i> 78:621-626 (1985).
AS	AR	Elliott <i>et al.</i> , "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to TNF- α : Safety, Clinical Efficacy and Control of the Acute Phase Response," <i>J. Cellular Biochemistry, Suppl.</i> 17B:145 (1993).
AS	AS	Elliott <i>et al.</i> , "Repeated Therapy with Monoclonal Antibody to Tumor Necrosis Factor α (cA2) in Patients with Rheumatoid Arthritis," <i>Lancet</i> 344:1125-1127 (1994).

EXAMINER

Judy De Cloux

DATE CONSIDERED

8-20-01/5-30-01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449	ATTY DOCKET NO. ABC-0001CIP	APPLICATION NO. 08 771,831
	APPLICANTS: Skurkovich <i>et al.</i>	
	FILING DATE: December 23, 1996	GROUP 1816 1644

INFORMATION DISCLOSURE STATEMENT

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)		
AT	Engleman <i>et al.</i> , "Treatment of NZB/NZW F ₁ Hybrid Mice with <i>Mycobacterium bovis</i> Strain BCG or Type II Interferon Preparations Accelerates Autoimmune Disease," <i>Arthr. Rheum.</i> 24:1396-1402 (1981).	
AU	Fattovich <i>et al.</i> , "Autoantibodies during Interferon- α Therapy for Chronic Hepatitis B," <i>Br. J. Med. Virol.</i> 34:132-135 (1991).	
AV	Feldman, <i>et al.</i> , "Interferons and Autoimmunity," In <i>IFN 9</i> , Academic Press, p.75 (1987).	
AW	Foulis <i>et al.</i> , "Immunoreactive α -Interferon in Insulin-Secreting β Cells in Type I Diabetes Mellitus," <i>Lancet</i> 2:1423-1427 (1987).	
AX	Gendelman <i>et al.</i> , "Induction of IFN α in Peripheral Blood Mononuclear Cells by HIV-Infected Monocytes," <i>J. Immunol.</i> 148:422-429 (1992).	
AY	Graninger <i>et al.</i> , "Induction of Systemic Lupus erythematosus by Interferon- γ in a Patient with Rheumatoid Arthritis," <i>J. Rheumatol.</i> 18:1621-1622 (1981).	
AZ	Gringeri <i>et al.</i> , "Anti-Alpha Interferon Immunization Safety and Immunogenicity in Asymptomatic HIV Positive Patients at High Risk of Disease Progression," <i>Cell. Mol. Biol.</i> 41(3): 381-387 (1995).	
BA	Gringeri <i>et al.</i> , "Absence of Clinical, Virological, and Immunological Signs of Progression in HIV-1-Infected Patients Receiving Active Anti-Interferon- α Immunization: A 30-Month Follow-Up Report," <i>J. Acquir. Immun. Defic. Syndr.</i> 13:55-67 (1996).	
BB	Heremans <i>et al.</i> , "Interferon Treatment of NZB Mice Accelerated Progression of Autoimmune Disease," <i>Infect. Immun.</i> 21:925-930 (1978).	
BC	Hess <i>et al.</i> , "Tumor Necrosis factor and Interferon as Prognostic Markers in Human Immunodeficiency Virus (HIV) Infection," <i>Infection</i> 19, Suppl. 2:S93-97 (1991).	
BD	Hirano <i>et al.</i> , "Interleukin-6 and Its Relation to Inflammation and Disease," <i>Clin. Immunol.</i> 62:S60-S65 (1992).	
BE	Holt <i>et al.</i> , "Cytokine Inter-Relationships and the Association with Disease Activity in Arthritis," <i>Brit. J. Rheum.</i> 21(11):725-733 (1992).	
BF	Hooks <i>et al.</i> , "Immune Interferon in the Circulation of Patients with Autoimmune Disease," <i>N. Engl. J. Med.</i> 301:5-8 (1979).	
BG	Johnson <i>et al.</i> , "The Role of Antimyosin Antibodies in Acute Myocardial Infarction," <i>Sem. Nuc. Med.</i> 19:238 (1989).	
EXAMINER <i>Am D. Cleve</i>		DATE CONSIDERED <i>5-20-01 8-30-01</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO.: ABC-0001CIP	APPLICATION NO. 08 771,831
	APPLICANTS: Skurkovich <i>et al.</i>	
	FILING DATE: December 23, 1996	GROUP 1846 1644

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)		
Am	BI1	Larrey <i>et al.</i> , "Exacerbation of Multiple Sclerosis after the Administration of Recombinant Human Interferon Alfa," <i>JAMA</i> 261:2065 (1989).
Am	BI	Lau <i>et al.</i> , "Regulation of Tumor Necrosis Factor Receptor Expression by Acid-Labile Interferon- α from AIDS Sera," <i>AIDS Research and Human Retroviruses</i> 7:545-552 (1991).
Am	BJ	Leinonen <i>et al.</i> , "Circulating Immune Complexes Containing Chlamydial Lipopolysaccharide in Acute Myocardial Infarction," <i>Microbiol. Path.</i> 9:67-73 (1990).
Am	BK	Libiková <i>et al.</i> , "Orbiviruses of the Kemerovo Complex and Neurological Disease," <i>Med. Microbiol. Immun.</i> 166:355-263 (1978).
Am	BL	Libiková <i>et al.</i> , "Assay of Interferon and Viral Antibodies in the Cerebrospinal Fluid in Clinical Neurology and Psychiatry," <i>Acta. Biol. Med. Germ.</i> 38:879-893 (1979).
Am	BM	Link <i>et al.</i> , "Increased Transforming Growth Factor- β , Interleukin-4, and Interferon- γ in Multiple Sclerosis," <i>Ann. Neurol.</i> 36:379-386 (1994).
Am	BN	Livden <i>et al.</i> , "In Situ Localization of Interferons in Psoriatic Lesions," <i>Arch. Dermatol. Res.</i> 281(6):392-397 (1989).
Am	BO	Machold <i>et al.</i> , "Interferon- γ Induced Exacerbation of Systemic Lupus Erythematosus," <i>J. Rheumat.</i> 17(6):831-832 (1990).
Am	BP	Matsuyama <i>et al.</i> , "Cytocidal Effect of Tumor Necrosis Factor on Cells Chronically Infected with Human Immunodeficiency Virus (HIV): Enhancement of HIV Replication," <i>Proc. Natl. Acad. Sci. USA</i> 86:2365-2509 (1989).
Am	BQ	Mauritz <i>et al.</i> , "Treatment with Gamma-Interferon Trigger the Onset of Collagen Arthritis in Mice," <i>Arthritis & Rheumatism</i> 31:1297-1304 (1988).
Am	BR	Meijer <i>et al.</i> , "Profiles of Cytokines (TNF α and IL-6) and Acute Phase Proteins (CRP and α 1AG) Related to the Disease Course in Patients with Systemic Lupus Erythematosus," <i>Lupus</i> 2:359-365 (1993).
Am	BS	Montalban <i>et al.</i> , "Antiphospholipid Antibodies in Cerebral Ischemia," <i>Stroke</i> 22:750-753 (1991).
Am	BT	Murakami <i>et al.</i> , "Diabetes Mellitus and Interferon- α Therapy," <i>Ann. Intern. Med.</i> 318 (August 1995).
Am	BU	Ohta <i>et al.</i> , ^{Supp. 1995} <i>Gastroenterol.</i> 88:209-210 (1991).
EXAMINER <i>Am D. Elmer</i>		DATE CONSIDERED 5-20-98/8-30-91
EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

FORM PTO-1449	ATTY DOCKET NO. ABC-0001CIP	APPLICATION NO. 08 771,831
	APPLICANTS: Skurkovich <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT	FILING DATE: December 23, 1996	GROUP 1816 1644

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)		
Am	BV	Panitch <i>et al.</i> , "Exacerbations of Multiple Sclerosis in Patients Treated with Gamma Interferon," <i>Lancet</i> 1:893-894 (1987).
Am	BW	Preble <i>et al.</i> , "Systemic Lupus Erythematosus: Presence in Human Serum of an Unusual Acid-Labile Leukocyte Interferon," <i>Science</i> 216:429-431 (1982).
Am	BX	Preble <i>et al.</i> , "Serum Interferon in Patients with Psychosis," <i>Am. J. Psychiatry</i> 142(10):1184-1186 (1985).
Am	BY	Quesada <i>et al.</i> , "Psoriasis and Alpha-Interferon," <i>Lancet</i> 2:1466-1468 (1986).
Am	BZ	Quesada <i>et al.</i> , "Clinical Toxicity of Interferons in Cancer Patients: A Review," <i>Clin. Oncol.</i> 2:234-243 (1986).
Am	CA	Remy <i>et al.</i> , "Experimental Autoimmune Thyroiditis Induced by Recombinant Interferon- γ ," <i>Immunol Today</i> 8:73 (1987).
Am	CB	Ronnblom, <i>et al.</i> , "Possible Induction of Systemic Lupus Erythematosus by Interferon- α Treatment in a Patient with a Malignant Carcinoid Tumour," <i>J. Intern. Med.</i> 227:207-210 (1990).
Am	CC	Ronnblom <i>et al.</i> , "Autoimmunity after Alpha-Interferon Therapy for Malignant Carcinoid Tumors," <i>Ann. Intern. Med.</i> 115:178-183 (1991).
Am	CD	Schattner <i>et al.</i> , "Review: Interferons and Autoimmunity," <i>Am. J. Med. Sci.</i> 295:532-544 (1988).
Am	CE	Schilling <i>et al.</i> , "Development of Systemic Lupus Erythematosus After Interferon Therapy for Chronic Myelogenous Leukemia," <i>Cancer</i> 68:1536-1537 (1991).
Am	CF	Shariff <i>et al.</i> , "Association between Tumor Necrosis Factor- α and Disease Progression in Patients with Multiple Sclerosis," <i>N. Engl. J. Med.</i> 325(7):467-472 (1992).
Am	CG	Shiozawa <i>et al.</i> , "Interferon-Alpha in Lupus Psychosis," <i>Arthr. Rheum.</i> 35:417-422 (1992).
Am	CH	Sinha <i>et al.</i> , "Autoimmune Diseases: The Failure of Self Tolerance," <i>Science</i> 248: 1380 (1990).
Am	CI	Skurkovich <i>et al.</i> , "Immunosuppressive Effect of an Anti-Interferon Serum," <i>Nature</i> 217:551-2 (1974).
Am	CJ	Skurkovich <i>et al.</i> , "The Probable Role of Interferon in Allergy," <i>Annals of Allergy</i> 35:356-360 (1975).
EXAMINER <i>Am D. Stone</i>		DATE CONSIDERED <i>5-20-01</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

Am D. Stone 5-30-01

FORM PTO-1449	ATTY. DOCKET NO. ABC-0001CIP	APPLICATION NO. 08 771,831 -
	APPLICANTS Skurkovich <i>et al.</i>	
	FILING DATE: December 23, 1996	GROUP: 1876/6 Y Y

INFORMATION DISCLOSURE STATEMENT

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)		
SK	CK	Skurkovich <i>et al.</i> , "Lymphocytes Cytotoxicity Towards Cells of Human Lymphoblastoid Lines in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus," <i>Annals of Allergy</i> 39:344-350 (1977).
SK	CL	Skurkovich <i>et al.</i> , "Interferon in the Serum of Autoimmune NZB/W and MRL/lpr/lpr Mice," <i>Annual International Congress for Interferon Research</i> (1981).
SK	CM	Skurkovich <i>et al.</i> , "Aberrant IFN May Help HIV Survive and Replicate; Its Removal in AIDS Patients May Halt This Process and Help Restore the Immune System," <i>J. IFN Res.</i> 12, Suppl. 1:S110 (1992).
SK	CN	Skurkovich <i>et al.</i> , "A Disturbance of Interferon Synthesis with the Hyperproduction of Unusual Kinds of Interferon Can Trigger Autoimmune Disease and Play a Pathogenic Role in AIDS: The Removal of These Interferons Can Be Therapeutic," <i>Med. Hypoth.</i> 41:177-185 (1993).
SK	CO	Skurkovich <i>et al.</i> , (Revised) "A Disturbance of Interferon Synthesis with the Hyperproduction of Unusual Kinds of Interferon Can Trigger Autoimmune Disease and Play a Pathogenic Role in AIDS: The Removal of These Interferons Can Be Therapeutic," <i>Med. Hypoth.</i> 42:27-35 (1994).
SK	CP	Uehara <i>et al.</i> , "Role of IFN- γ in the Development of the Murine Acquired Immunodeficiency Syndrome, MAIDS," <i>J. Interferon Res.</i> 13, Suppl. 1: PW6-9 (Oct. 1993).
SK	CQ	Vadhan-Raj <i>et al.</i> , "Immunological Variables as Predictors of Prognosis in Patients with Kaposi's Sarcoma and the Acquired Immunodeficiency Syndrome," <i>Cancer Res.</i> 46:417 (1986).
SK	CR	Van Snick <i>et al.</i> , "Interleukin-6: An Overview," <i>Ann. Rev. Immunol.</i> 8:253-278 (1990).
SK	CS	Vento <i>et al.</i> , "Rapid Decline of CD4+ Cells after IFN α Treatment in HIV-1 Infection," <i>Lancet</i> 341 (April 10, 1993).
SK	CT	Vileek <i>et al.</i> , In <i>AIDS: The Epidemic of Kaposi's Syndrome and Opportunistic Infections</i> , A.E. Friedman-Kien & L.J. Laubenstein, eds. Masson Publishing, New York, New York, 1986.
SK	CU	Wood <i>et al.</i> , "In Situ Hybridization of IL-6 in Rheumatoid Arthritis," <i>Clin. Exp. Immunol.</i> 87:183-189 (1992).
	CV	
	CW	
	CX	
EXAMINER <i>My DeClone</i>		DATE CONSIDERED 8-20-01 5-30/00
EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		